Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Purple Biotech Ltd. (PPBT)

2.04   0.02 (0.99%) 11-25 12:56
Open: 1.99 Pre. Close: 2.02
High: 2.04 Low: 1.99
Volume: 4,687 Market Cap: 37(M)

Technical analysis

as of: 2022-11-25 1:59:40 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.45     One year: 2.59
Support: Support1: 1.91    Support2: 1.59
Resistance: Resistance1: 2.1    Resistance2: 2.22
Pivot: 2.06
Moving Average: MA(5): 2.02     MA(20): 2.06
MA(100): 2.23     MA(250): 2.82
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 24.4     %D(3): 27.3
RSI: RSI(14): 46.1
52-week: High: 4.5  Low: 1.83
Average Vol(K): 3-Month: 82 (K)  10-Days: 40 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PPBT ] has closed above bottom band by 32.6%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.02 - 2.04 2.04 - 2.05
Low: 1.94 - 1.95 1.95 - 1.97
Close: 1.99 - 2.02 2.02 - 2.05

Company Description

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Headline News

Fri, 18 Nov 2022
Percentage of Brake Safety Week out-of-service orders holds steady in US - FreightWaves

Tue, 15 Nov 2022
Purple Biotech (PPBT) Presents New Data on Mechanism of Action for CM24 -

Tue, 08 Nov 2022
Purple Biotech Reports Third Quarter 2022 Financial Results - Yahoo Finance

Wed, 02 Nov 2022
Purple Biotech Appoints Lior Fhima as Chief Financial Officer - Yahoo Finance

Mon, 17 Oct 2022
Purple Biotech's Assets Are First In Class For Solid Tumor Treatment, Analyst Says - Purple Biotech (NASD - Benzinga

Thu, 11 Aug 2022
Purple Biotech Stock: Should I invest? - Value the Markets

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 18 (M)
Shares Float 0 (M)
% Held by Insiders 0 (%)
% Held by Institutions 0.6 (%)
Shares Short 872 (K)
Shares Short P.Month 886 (K)

Stock Financials

EPS -1.09
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.86
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -19.7
Return on Equity (ttm) -33.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.01
Sales Per Share 0
EBITDA (p.s.) -1.14
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -1.88
PEG Ratio 0
Price to Book value 0.7
Price to Sales 0
Price to Cash Flow -2.28

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-08-20
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.